HC Wainwright Has Negative Outlook of ETON Q2 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at HC Wainwright reduced their Q2 2025 earnings estimates for shares of Eton Pharmaceuticals in a research report issued on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS and Q4 2025 earnings at $0.19 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). The business had revenue of $17.28 million during the quarter, compared to the consensus estimate of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.

A number of other equities research analysts have also recently issued reports on ETON. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday. B. Riley reiterated a “buy” rating and issued a $26.00 price objective (up from $24.00) on shares of Eton Pharmaceuticals in a report on Friday.

Eton Pharmaceuticals Trading Down 3.9%

Shares of NASDAQ:ETON opened at $18.93 on Friday. The stock has a market capitalization of $507.66 million, a PE ratio of -86.05 and a beta of 1.22. Eton Pharmaceuticals has a 1 year low of $3.18 and a 1 year high of $21.48. The firm has a fifty day moving average price of $14.82 and a 200 day moving average price of $13.89.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Eton Pharmaceuticals by 18.3% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock valued at $141,000 after acquiring an additional 1,634 shares during the period. XTX Topco Ltd boosted its holdings in Eton Pharmaceuticals by 29.6% during the fourth quarter. XTX Topco Ltd now owns 14,655 shares of the company’s stock valued at $195,000 after acquiring an additional 3,351 shares during the period. AlphaQuest LLC acquired a new position in shares of Eton Pharmaceuticals during the first quarter valued at about $53,000. Tower Research Capital LLC TRC acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at about $86,000. Finally, Quantbot Technologies LP acquired a new position in shares of Eton Pharmaceuticals during the first quarter valued at about $101,000. 27.86% of the stock is currently owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.